Nycomed and Amersham to Merge
Executive Summary
Since its failed merger with generics giant Ivax two years ago, Nycomed has been looking for a partner to help it out of the morass of a difficult contrast media market. With larger purchasers on the rise, prices went south, catching Nycomed off guard. With Amersham, the company will be able to broaden its product line, offering both wider product choice to customers and a more efficient cost structure.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.